"Preview" Icon

Eptinezumab

Need More Information?

Read answers to frequently asked questions about BioHarmony's centralized semantic drug data sets and what they can do for you on our

Vyepti (eptinezumab) is an antibody pharmaceutical. Eptinezumab was first approved as Vyepti on 2020-02-21. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1 and calcitonin gene-related peptide 2.

$325 / month – $3,000 / year

Clear

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Trade Name

 Vyepti

Common Name

 eptinezumab

ChEMBL ID

 CHEMBL3833320

Indication

Drug Class

 Monoclonal antibodies: humanized, neural indications

Image (chem structure or protein)

Eptinezumab structure rendering

$325 / month – $3,000 / year

Clear

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Every Drug Dataset Includes...

Full Drug Information

Including:

Trade name (FDA, EMA)

Drug common name

Description

Classification

Drug class

Image (chemical or protein structure)

Protein Data Bank ID

Structure (InChI/SMILES or Protein Sequence)

CAS-ID

RxCUI

ChEMBL ID

ChEBI ID

PubChem CID

DrugBank ID

Indications

Including:

Agency approved indications

Phase 1 Indications

Phase 2 Indications

Phase 3 Indications

Phase 4 Indications

MeSH identifiers

Ontology identifiers

Target Information

Including:

Agency Approved Targets

Alternative Targets

Gene name

Gene synonyms

NCBI Gene ID

Protein name

Protein synonyms

Uniprot ID

Orthologs

Clinical Variant Information

Including:

ClinVar ID

Target mutation

Effect

Evaluation date

PharmGKB level

Clinical Trial Information

Including:

NCT ID

Trial Timeline

Results

Phase

Expanded Access

Official Title

Sponsor

Indications / Phase Indications

Study Type

Enrollment

Inclusion Criteria

Exclusion Criteria

Links to Clinical Trials

Reimbursement Codes

Including:

ICD-10

ATC

HCPCS

Safety Information

Including:

Black Box Warnings

Adverse Events

Adverse Reactions

Expedite Criteria

Trend Information

Including:

Top, trending, and new metadata terms in the following categories:

Disease or Syndrome

Pharmacological Substances

Biological Entities

Laboratory Procedures

Commercial Information

Including:

Company (FDA, EMA)

Approval Date (FDA, EMA)

Exclusivity

Patent Expiration

Generics and Biosimilars (FDA, EMA)

Drug Labels

Economic Information

Including:

Company

Annual revenue

Quarterly revenue

Global sales

US sales

Non-US sales

Full dataset compatible with-

SQL logo
SQL for web applications
<strong>R</strong> for statistical modeling
R for statistical modeling
Spotfire and tableau logos
Spotfire & Tableau for visualization
<strong>CSV</strong> export file format
CSV export file format
JSON logo
JSON export file format
XLSX logo
XLSX export file format

Continually updated information available as a yearly subscription for individual drug-of-interest.

$325 / month – $3,000 / year

Clear

Schedule a demo to see what you get or contact us for additional or enterprise purchasing options.